Clarius Group LLC Sells 32,258 Shares of Haleon PLC Sponsored ADR (NYSE:HLN)

Clarius Group LLC lowered its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 55.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,269 shares of the company's stock after selling 32,258 shares during the period. Clarius Group LLC's holdings in Haleon were worth $270,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of HLN. Opal Wealth Advisors LLC acquired a new stake in shares of Haleon in the 1st quarter valued at $29,000. FIL Ltd boosted its stake in shares of Haleon by 45.7% in the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after purchasing an additional 1,270 shares in the last quarter. Addison Advisors LLC boosted its stake in shares of Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,106 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Haleon by 22.6% in the 4th quarter. Lindbrook Capital LLC now owns 9,355 shares of the company's stock valued at $89,000 after purchasing an additional 1,724 shares in the last quarter. Finally, GeoWealth Management LLC boosted its stake in shares of Haleon by 67.4% in the 4th quarter. GeoWealth Management LLC now owns 9,876 shares of the company's stock valued at $94,000 after purchasing an additional 3,975 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HLN shares. Barclays restated an "overweight" rating on shares of Haleon in a research note on Tuesday, May 6th. HSBC reaffirmed a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a report on Monday, March 3rd. BNP Paribas raised Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Finally, Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Five analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Trading Up 0.7%

NYSE:HLN traded up $0.07 on Monday, hitting $10.48. 12,636,777 shares of the stock were exchanged, compared to its average volume of 9,135,263. The stock has a market capitalization of $47.13 billion, a price-to-earnings ratio of 26.87, a P/E/G ratio of 2.96 and a beta of 0.31. Haleon PLC Sponsored ADR has a 52 week low of $8.25 and a 52 week high of $11.42. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.78 and a current ratio of 0.98. The company's 50-day moving average price is $10.70 and its 200 day moving average price is $10.11.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.